A carregar...
Immunotherapeutic approaches for small-cell lung cancer
Immune-checkpoint inhibitors (ICIs) are approved in the first-line and third-line settings for patients with extensive-stage or relapsed small-cell lung cancer (SCLC), respectively. In the first-line setting, the addition of the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezolizumab to...
Na minha lista:
| Publicado no: | Nat Rev Clin Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212527/ https://ncbi.nlm.nih.gov/pubmed/32055013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41571-019-0316-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|